New cases of thalidomide embryopathy in Brazil
Thalidomide is the best known human teratogen. Although withdrawn from the market in 1961, thalidomide was remarketed after 1965 in several countries, for the treatment of erythema nodosum leprosum. Thalidomide has a potent immunomodulatory property and has now a number of approved and off‐label use...
Gespeichert in:
| Veröffentlicht in: | Birth defects research. A Clinical and molecular teratology 2007-09, Vol.79 (9), p.671-672 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 672 |
|---|---|
| container_issue | 9 |
| container_start_page | 671 |
| container_title | Birth defects research. A Clinical and molecular teratology |
| container_volume | 79 |
| creator | Schuler‐Faccini, Lavinia Soares, Rosa Castalia Franca de Sousa, Artur Custodio Moreira Maximino, Claudia Luna, Expedito Schwartz, Ida Vanessa Doderlein Waldman, Carolina Castilla, Eduardo Enrique |
| description | Thalidomide is the best known human teratogen. Although withdrawn from the market in 1961, thalidomide was remarketed after 1965 in several countries, for the treatment of erythema nodosum leprosum. Thalidomide has a potent immunomodulatory property and has now a number of approved and off‐label uses in dermatologic, oncologic, infectious and gastrointestinal conditions. In the U.S., FDA approved the use of thalidomide in 1998, but no cases of thalidomide embriophaty were registered after that. Since 1996 no new cases were reported in Latin America. However, the Teratogen Information Service (TIS) Porto Alegre, recorded three new cases of thalidomide embriophaty born in Brazil since 2005. Considering that these three cases were not registered through a systematic surveillance system, but that came to our attention through a series of coincidental random events, it can be assumed that the actual occurrence of affected babies by thalidomide continues being as frequent as denounced ten years ago. Birth Defects Research (Part A), 2007. © 2007 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/bdra.20384 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_bdra_20384</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>BDRA20384</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4294-75ad38e0f6f99450d703eb0bbeb8ffc539959793b5a7c40461861b1618604d8c3</originalsourceid><addsrcrecordid>eNp9j8tKxDAYRoMozji68QGka6H1T5M0zXIu3mBQEF2HXJlKa4dkZKhPb2sH3bn6vsXhwEHoEkOGAfIbbYPKciAlPUJTzGieAi_g-PezfILOYnzvWcI5P0UTzAteMJFPUfbk9olR0cWk9cluo-rKtk1lXeIaHbp2q3abLqk-kkVQX1V9jk68qqO7OOwMvd3dvi4f0vXz_eNyvk4NzQVNOVOWlA584YWgDCwH4jRo7XTpvWFECCa4IJopbijQApcF1ngYoLY0ZIauR68JbYzBebkNVaNCJzHIIVoO0fInuoevRnj7qRtn_9BDZQ_gEdhXtev-UcnF6mU-Sr8Bi5lgHg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>New cases of thalidomide embryopathy in Brazil</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Schuler‐Faccini, Lavinia ; Soares, Rosa Castalia Franca ; de Sousa, Artur Custodio Moreira ; Maximino, Claudia ; Luna, Expedito ; Schwartz, Ida Vanessa Doderlein ; Waldman, Carolina ; Castilla, Eduardo Enrique</creator><creatorcontrib>Schuler‐Faccini, Lavinia ; Soares, Rosa Castalia Franca ; de Sousa, Artur Custodio Moreira ; Maximino, Claudia ; Luna, Expedito ; Schwartz, Ida Vanessa Doderlein ; Waldman, Carolina ; Castilla, Eduardo Enrique</creatorcontrib><description>Thalidomide is the best known human teratogen. Although withdrawn from the market in 1961, thalidomide was remarketed after 1965 in several countries, for the treatment of erythema nodosum leprosum. Thalidomide has a potent immunomodulatory property and has now a number of approved and off‐label uses in dermatologic, oncologic, infectious and gastrointestinal conditions. In the U.S., FDA approved the use of thalidomide in 1998, but no cases of thalidomide embriophaty were registered after that. Since 1996 no new cases were reported in Latin America. However, the Teratogen Information Service (TIS) Porto Alegre, recorded three new cases of thalidomide embriophaty born in Brazil since 2005. Considering that these three cases were not registered through a systematic surveillance system, but that came to our attention through a series of coincidental random events, it can be assumed that the actual occurrence of affected babies by thalidomide continues being as frequent as denounced ten years ago. Birth Defects Research (Part A), 2007. © 2007 Wiley‐Liss, Inc.</description><identifier>ISSN: 1542-0752</identifier><identifier>EISSN: 1542-0760</identifier><identifier>DOI: 10.1002/bdra.20384</identifier><identifier>PMID: 17676592</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Abnormalities, Drug-Induced - etiology ; Abnormalities, Multiple - chemically induced ; Adolescent ; Adult ; Brazil ; Contraindications ; Female ; Humans ; Infant, Newborn ; Limb Deformities, Congenital - chemically induced ; Male ; phocomelia ; Pregnancy ; Registries ; teratogenesis ; Teratogens - toxicity ; thalidomide ; Thalidomide - toxicity ; Twins</subject><ispartof>Birth defects research. A Clinical and molecular teratology, 2007-09, Vol.79 (9), p.671-672</ispartof><rights>Copyright © 2007 Wiley‐Liss, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4294-75ad38e0f6f99450d703eb0bbeb8ffc539959793b5a7c40461861b1618604d8c3</citedby><cites>FETCH-LOGICAL-c4294-75ad38e0f6f99450d703eb0bbeb8ffc539959793b5a7c40461861b1618604d8c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fbdra.20384$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fbdra.20384$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17676592$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schuler‐Faccini, Lavinia</creatorcontrib><creatorcontrib>Soares, Rosa Castalia Franca</creatorcontrib><creatorcontrib>de Sousa, Artur Custodio Moreira</creatorcontrib><creatorcontrib>Maximino, Claudia</creatorcontrib><creatorcontrib>Luna, Expedito</creatorcontrib><creatorcontrib>Schwartz, Ida Vanessa Doderlein</creatorcontrib><creatorcontrib>Waldman, Carolina</creatorcontrib><creatorcontrib>Castilla, Eduardo Enrique</creatorcontrib><title>New cases of thalidomide embryopathy in Brazil</title><title>Birth defects research. A Clinical and molecular teratology</title><addtitle>Birth Defects Res A Clin Mol Teratol</addtitle><description>Thalidomide is the best known human teratogen. Although withdrawn from the market in 1961, thalidomide was remarketed after 1965 in several countries, for the treatment of erythema nodosum leprosum. Thalidomide has a potent immunomodulatory property and has now a number of approved and off‐label uses in dermatologic, oncologic, infectious and gastrointestinal conditions. In the U.S., FDA approved the use of thalidomide in 1998, but no cases of thalidomide embriophaty were registered after that. Since 1996 no new cases were reported in Latin America. However, the Teratogen Information Service (TIS) Porto Alegre, recorded three new cases of thalidomide embriophaty born in Brazil since 2005. Considering that these three cases were not registered through a systematic surveillance system, but that came to our attention through a series of coincidental random events, it can be assumed that the actual occurrence of affected babies by thalidomide continues being as frequent as denounced ten years ago. Birth Defects Research (Part A), 2007. © 2007 Wiley‐Liss, Inc.</description><subject>Abnormalities, Drug-Induced - etiology</subject><subject>Abnormalities, Multiple - chemically induced</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Brazil</subject><subject>Contraindications</subject><subject>Female</subject><subject>Humans</subject><subject>Infant, Newborn</subject><subject>Limb Deformities, Congenital - chemically induced</subject><subject>Male</subject><subject>phocomelia</subject><subject>Pregnancy</subject><subject>Registries</subject><subject>teratogenesis</subject><subject>Teratogens - toxicity</subject><subject>thalidomide</subject><subject>Thalidomide - toxicity</subject><subject>Twins</subject><issn>1542-0752</issn><issn>1542-0760</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9j8tKxDAYRoMozji68QGka6H1T5M0zXIu3mBQEF2HXJlKa4dkZKhPb2sH3bn6vsXhwEHoEkOGAfIbbYPKciAlPUJTzGieAi_g-PezfILOYnzvWcI5P0UTzAteMJFPUfbk9olR0cWk9cluo-rKtk1lXeIaHbp2q3abLqk-kkVQX1V9jk68qqO7OOwMvd3dvi4f0vXz_eNyvk4NzQVNOVOWlA584YWgDCwH4jRo7XTpvWFECCa4IJopbijQApcF1ngYoLY0ZIauR68JbYzBebkNVaNCJzHIIVoO0fInuoevRnj7qRtn_9BDZQ_gEdhXtev-UcnF6mU-Sr8Bi5lgHg</recordid><startdate>200709</startdate><enddate>200709</enddate><creator>Schuler‐Faccini, Lavinia</creator><creator>Soares, Rosa Castalia Franca</creator><creator>de Sousa, Artur Custodio Moreira</creator><creator>Maximino, Claudia</creator><creator>Luna, Expedito</creator><creator>Schwartz, Ida Vanessa Doderlein</creator><creator>Waldman, Carolina</creator><creator>Castilla, Eduardo Enrique</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200709</creationdate><title>New cases of thalidomide embryopathy in Brazil</title><author>Schuler‐Faccini, Lavinia ; Soares, Rosa Castalia Franca ; de Sousa, Artur Custodio Moreira ; Maximino, Claudia ; Luna, Expedito ; Schwartz, Ida Vanessa Doderlein ; Waldman, Carolina ; Castilla, Eduardo Enrique</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4294-75ad38e0f6f99450d703eb0bbeb8ffc539959793b5a7c40461861b1618604d8c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Abnormalities, Drug-Induced - etiology</topic><topic>Abnormalities, Multiple - chemically induced</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Brazil</topic><topic>Contraindications</topic><topic>Female</topic><topic>Humans</topic><topic>Infant, Newborn</topic><topic>Limb Deformities, Congenital - chemically induced</topic><topic>Male</topic><topic>phocomelia</topic><topic>Pregnancy</topic><topic>Registries</topic><topic>teratogenesis</topic><topic>Teratogens - toxicity</topic><topic>thalidomide</topic><topic>Thalidomide - toxicity</topic><topic>Twins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schuler‐Faccini, Lavinia</creatorcontrib><creatorcontrib>Soares, Rosa Castalia Franca</creatorcontrib><creatorcontrib>de Sousa, Artur Custodio Moreira</creatorcontrib><creatorcontrib>Maximino, Claudia</creatorcontrib><creatorcontrib>Luna, Expedito</creatorcontrib><creatorcontrib>Schwartz, Ida Vanessa Doderlein</creatorcontrib><creatorcontrib>Waldman, Carolina</creatorcontrib><creatorcontrib>Castilla, Eduardo Enrique</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Birth defects research. A Clinical and molecular teratology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schuler‐Faccini, Lavinia</au><au>Soares, Rosa Castalia Franca</au><au>de Sousa, Artur Custodio Moreira</au><au>Maximino, Claudia</au><au>Luna, Expedito</au><au>Schwartz, Ida Vanessa Doderlein</au><au>Waldman, Carolina</au><au>Castilla, Eduardo Enrique</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New cases of thalidomide embryopathy in Brazil</atitle><jtitle>Birth defects research. A Clinical and molecular teratology</jtitle><addtitle>Birth Defects Res A Clin Mol Teratol</addtitle><date>2007-09</date><risdate>2007</risdate><volume>79</volume><issue>9</issue><spage>671</spage><epage>672</epage><pages>671-672</pages><issn>1542-0752</issn><eissn>1542-0760</eissn><abstract>Thalidomide is the best known human teratogen. Although withdrawn from the market in 1961, thalidomide was remarketed after 1965 in several countries, for the treatment of erythema nodosum leprosum. Thalidomide has a potent immunomodulatory property and has now a number of approved and off‐label uses in dermatologic, oncologic, infectious and gastrointestinal conditions. In the U.S., FDA approved the use of thalidomide in 1998, but no cases of thalidomide embriophaty were registered after that. Since 1996 no new cases were reported in Latin America. However, the Teratogen Information Service (TIS) Porto Alegre, recorded three new cases of thalidomide embriophaty born in Brazil since 2005. Considering that these three cases were not registered through a systematic surveillance system, but that came to our attention through a series of coincidental random events, it can be assumed that the actual occurrence of affected babies by thalidomide continues being as frequent as denounced ten years ago. Birth Defects Research (Part A), 2007. © 2007 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>17676592</pmid><doi>10.1002/bdra.20384</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1542-0752 |
| ispartof | Birth defects research. A Clinical and molecular teratology, 2007-09, Vol.79 (9), p.671-672 |
| issn | 1542-0752 1542-0760 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_bdra_20384 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Abnormalities, Drug-Induced - etiology Abnormalities, Multiple - chemically induced Adolescent Adult Brazil Contraindications Female Humans Infant, Newborn Limb Deformities, Congenital - chemically induced Male phocomelia Pregnancy Registries teratogenesis Teratogens - toxicity thalidomide Thalidomide - toxicity Twins |
| title | New cases of thalidomide embryopathy in Brazil |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T01%3A00%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20cases%20of%20thalidomide%20embryopathy%20in%20Brazil&rft.jtitle=Birth%20defects%20research.%20A%20Clinical%20and%20molecular%20teratology&rft.au=Schuler%E2%80%90Faccini,%20Lavinia&rft.date=2007-09&rft.volume=79&rft.issue=9&rft.spage=671&rft.epage=672&rft.pages=671-672&rft.issn=1542-0752&rft.eissn=1542-0760&rft_id=info:doi/10.1002/bdra.20384&rft_dat=%3Cwiley_cross%3EBDRA20384%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17676592&rfr_iscdi=true |